Idogen AB
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment wi… Read more
Idogen AB (IDOGEN) - Total Assets
Latest total assets as of March 2023: Skr5.12 Million SEK
Based on the latest financial reports, Idogen AB (IDOGEN) holds total assets worth Skr5.12 Million SEK as of March 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Idogen AB - Total Assets Trend (2014–2022)
This chart illustrates how Idogen AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Idogen AB - Asset Composition Analysis
Current Asset Composition (December 2022)
Idogen AB's total assets of Skr5.12 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 59.0% |
| Accounts Receivable | Skr2.67 Million | 29.7% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr1.00K | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2022)
This chart illustrates how Idogen AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Idogen AB's current assets represent 100.0% of total assets in 2022, an increase from 82.2% in 2014.
- Cash Position: Cash and equivalents constituted 59.0% of total assets in 2022, down from 76.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 17.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 29.7% of total assets.
Idogen AB Competitors by Total Assets
Key competitors of Idogen AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
|
Panagene Inc
KQ:046210
|
Korea | ₩101.91 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Biotoxtech Co. Ltd
KQ:086040
|
Korea | ₩132.45 Billion |
|
Peptron Inc
KQ:087010
|
Korea | ₩183.74 Billion |
|
Hadasit Bio
TA:HDST
|
Israel | ILA14.67 Million |
Idogen AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Idogen AB generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Idogen AB is currently not profitable relative to its asset base.
Idogen AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.66 | 9.72 | 2.03 |
| Quick Ratio | 1.66 | 9.72 | 2.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr2.03 Million | Skr 40.47 Million | Skr 16.60 Million |
Idogen AB - Advanced Valuation Insights
This section examines the relationship between Idogen AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.19 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -61.0% |
| Total Assets | Skr9.00 Million |
| Market Capitalization | $940.11K USD |
Valuation Analysis
Below Book Valuation: The market values Idogen AB's assets below their book value (0.10 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Idogen AB's assets decreased by 61.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Idogen AB (2014–2022)
The table below shows the annual total assets of Idogen AB from 2014 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | Skr9.00 Million | -61.00% |
| 2021-12-31 | Skr23.07 Million | -54.63% |
| 2020-12-31 | Skr50.84 Million | +63.02% |
| 2019-12-31 | Skr31.19 Million | -56.49% |
| 2018-12-31 | Skr71.67 Million | +62.21% |
| 2017-12-31 | Skr44.19 Million | +113.79% |
| 2016-12-31 | Skr20.67 Million | +55.65% |
| 2015-12-31 | Skr13.28 Million | +234.52% |
| 2014-12-31 | Skr3.97 Million | -- |